This technology includes a new reverse genetics-based approach that generates Crimean-Congo hemorrhagic fever virus (CCHF) viral replicon particles (CCHF VRPs) to be developed into a vaccine for CCHFV. With mortality rates as high as 80% and with no FDA-approved vaccines or therapeutics, CCHFV is considered a dangerous emerging human pathogen. Unlike transcriptionally competent virus like particles (tc-VLPs), that only include CCHFV virus proteins and minigenome RNA, VRPs undergo one full round of replication closely mimicking authentic viral replication. Unlike most vaccine approaches tested, VRPs do not solely rely on the expression of hypervariable GPC gene, which is unlikely on its own, to confer adequate protection against divergent strains of CCHFV. In contrast, VRPs abundantly produce the most conserved viral proteins and consequently are expected to build protective immunity against genetically divergent strains of CCHFV. We recently demonstrated that CCHF VRPs can be produced; these undergo only one round of replication, but can be amplified by expressing GPC in trans and that this approach can infer in a single dose complete protection in a CCHFV mouse model.